Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-03049423 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-03049423 | ACTIVE_COMPARATOR | Cohorts 1 through 3 were healthy young adult volunteers; cohorts 4 and 5 were healthy elderly adult volunteers |
| Drug | PLACEBO_COMPARATOR | Placebo in oral solution, given once daily for 14 days |
| Name | Type | Description |
|---|---|---|
| PF-03049423 | DRUG | PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers |
| Placebo | DRUG | Placebo in oral solution, given once daily for 14 days |
Inclusion Criteria: * Healthy persons, male or female. * For the healthy young adult cohort, subjects must be 18 to 50 years old, inclusive. * For the healthy elderly adult cohort, subjects must be 51 to 99 years old, inclusive. * Body Mass Index (BMI) of 18 to 35; and a total body weight \>50 kg (...
PF-03049423 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is a PDE5A inhibitor that has been studied in Phase 1 clinical development. The specific therapeutic indication for PF-03049423 has not been disclosed, and the compound has been evaluated in healthy adult and older adult volunteers rather than in a patient population.
PF-03049423 targets PDE5A, also known as phosphodiesterase type 5A. It is classified as a PDE5A inhibitor, meaning it acts by inhibiting the enzymatic activity of this phosphodiesterase. This target class places PF-03049423 among small molecule PDE5A inhibitors, a mechanism that modulates cyclic nucleotide signaling through PDE5A inhibition.
PF-03049423 is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the sponsor of the clinical program for this investigational PDE5A inhibitor small molecule. No other developer or partner is associated with PF-03049423 based on its development record.
PF-03049423 is in Phase 1 clinical development. It is an investigational agent and is not approved for any indication. The Phase 1 program has been completed, with one completed trial and no active trials currently listed for PF-03049423.
PF-03049423 has been studied in one Phase 1 trial, NCT01161069, titled a study to evaluate the safety and tolerability of different doses of PF-03049423 in healthy adult volunteers and healthy older volunteers. That trial was completed, enrolled 48 participants, was randomized, double blind, and placebo controlled, and was conducted in Belgium.
The PF-03049423 Phase 1 trial NCT01161069 was a randomized, double blind, placebo controlled study of different doses in healthy adult and healthy older volunteers. It enrolled 48 participants of all sexes, aged 18 years and older, and was conducted in Belgium. The trial has been completed.